RxDoctor Payments Data

Nga Yan Siu, DO

Ophthalmology · Southampton, NYNPI 1902284169

Payments from drug & device makers

$2,816in general payments, 2019–2025

Across 69 payments — averaging $40.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$647
  • Alcon$595
  • Aerie Pharmaceuticals, Inc.$362
  • Biotissue Holdings Inc.$278
  • Johnson & Johnson Surgical Vision, Inc.$224
  • Oyster Point Pharma, Inc.$163
  • plus $546 from 11 others

What the payments were for

  • Food & beverage$2,816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,816 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$332,499
Medicare patients
794
Services billed
3,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine111$161,525
RocklatanNetarsudil Mesylat/Latanoprost105$61,393
LumiganBimatoprost72$37,472
XiidraLifitegrast16$29,446
SimbrinzaBrinzolamide/Brimonidine Tart94$29,004
RhopressaNetarsudil Mesylate54$25,309
Alphagan PBrimonidine Tartrate23$17,034
Brimonidine Tartrate202$12,889
VyzultaLatanoprostene Bunod16$8,977
Cyclosporine12$8,854
Timolol Maleate149$7,135
Brinzolamide26$6,011
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$5,873
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat316$5,862
Latanoprost453$5,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$647$216,031206 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$362$86,702159 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$100$38,42232 claims
AlconSimbrinza$595$29,00494 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Southampton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →